

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Parenchymal lung abnormalities, tocilizumab plus dexamethasone vs dexamethasone, SARS-CoV-2 entry into cells, vaccine vs Omicron BA.2

Peer reviewed journals featured:

- A systematic review on parenchymal lung abnormalities after hospitalisation for COVID-19 and viral pneumonitis [here](#)
- A randomised clinical trial of tocilizumab plus dexamethasone vs dexamethasone in patients with moderate-to-severe COVID-19 pneumonia [here](#)
- A narrative review on SARS-CoV-2 cell entry and budding in human airway epithelium [here](#)
- Observational studies on:
 - Outcomes of SARS-CoV-2 infection in children and young people with pre-existing rheumatic and musculoskeletal diseases [here](#)
 - The influence of risk perceptions on close contact frequency during COVID-19 [here](#)
 - Prevalence of SARS-CoV-2 antibodies in Belgian healthcare and university staff [here](#)
 - Reporting and data sharing level for COVID-19 vaccine trials [here](#)
 - Enoxaparin and inhibition of transmembrane protease 2 (TMPRSS2) [here](#)
- A modelling study estimating COVID-19 cases and hospitalisations averted by case investigation and contact tracing in the US [here](#)
- Commentary on:
 - Strategies to promote equity in COVID-19 antiviral treatment in the US [here](#)
 - The decline of invasive meningococcal disease and influenza in Australia during COVID-19 [here](#)
 - Factors influencing estimated effectiveness of COVID-19 vaccines in non-randomised studies [here](#)

Letters and correspondence discussed:

- SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses in the UK [here](#)
- Scalable biomimetic SARS-CoV-2 nanovaccines with robust protective immune responses [here](#)

Pre-peer review articles featured:

- COVID-19 vaccine effectiveness against the Omicron BA.2 variant in England [here](#)
- Relative effectiveness of 4 doses compared to 3 doses of Comirnaty (Pfizer) vaccine in Israel [here](#)
- Comirnaty (Pfizer) vaccine effectiveness against reported Delta and Omicron infection among adolescents in Norway [here](#)
- Impact of vaccination, prior infection, and therapy on Delta and Omicron variants [here](#)
- Comirnaty (Pfizer) booster dose in a CoronaVac primary vaccination protocol improves neutralisation of Omicron variant [here](#)
- The modified COVID-19 Yorkshire Rehabilitation Scale (C19-YRSm) patient-reported outcome measure for post-acute COVID-19 syndrome [here](#)

Guidance and reports

- The UK Health Security Agency published an update on SARS-CoV-2 variants of concern and variants under investigation [here](#)

News and blogs

- Health workforce: not normal, not safe, but it can be fixed [here](#)
- Fourth COVID-19 shot in Australia [here](#)
- Who will be eligible for free testing from 1 April in the UK? [here](#)
- Moderna will ask for authorisation for vaccine for infants and children [here](#)
- Can drugs reduce the risk of post-acute COVID-19 syndrome? [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).